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Alpha-synuclein (aSyn) is a vertebrate protein, normally
found within the presynaptic nerve terminal and nucleus,
which is known to form somatic and neuritic aggregates in
certain neurodegenerative diseases. Disease-associated aggregates of aSyn are heavily phosphorylated at serine-129 (pSyn),
while normal aSyn protein is not. Within the nucleus, aSyn can
directly bind DNA, but the mechanism of binding and the
potential modulatory roles of phosphorylation are poorly understood. Here we demonstrate using a combination of electrophoretic mobility shift assay and atomic force microscopy
approaches that both aSyn and pSyn can bind DNA within the
major groove, in a DNA length-dependent manner and with
little speciﬁcity for DNA sequence. Our data are consistent
with a model in which multiple aSyn molecules bind a single
300 base pair (bp) DNA molecule in such a way that stabilizes
the DNA in a bent conformation. We propose that serine-129
phosphorylation decreases the ability of aSyn to both bind
and bend DNA, as aSyn binds 304 bp circular DNA forced into
a bent shape, but pSyn does not. Two aSyn paralogs, beta- and
gamma-synuclein, also interact with DNA differently than
aSyn, and do not stabilize similar DNA conformations. Our
work suggests that reductions in aSyn’s ability to bind and bend
DNA induced by serine-129 phosphorylation may be important
for modulating aSyn’s known roles in DNA metabolism,
including the regulation of transcription and DNA repair.

Alpha-synuclein (aSyn) is a 140 amino acid–long protein
found in vertebrates, where it is known to localize to the
presynaptic nerve terminal (1–3) and nucleus (1, 4–9). aSyn is
linked to genetic forms of parkinsonism in families with an
autosomal dominant inheritance pattern. The ﬁrst such point
mutation found (A53T) was in the N-terminal phospholipidbinding domain (10). Since then, ﬁve additional point
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mutations (A30P, E46K, H50Q, G51D, A53E) have been suggested to cause parkinsonism (11–17), and all occur within a
24 amino acid stretch of the N-terminal phospholipid-binding
domain, indicating the potential importance of this region in
triggering disease. This initial genetic linkage between aSyn
and parkinsonism led to the discovery that the pathological
hallmark of sporadic (nongenetic) Parkinson’s Disease, the
Lewy body, is composed primarily of misfolded aSyn (18), in a
combination of ﬁbrillar and granular aggregation states
(19, 20). A subset of prominent neurodegenerative conditions
in addition to Parkinson’s Disease, including Dementia with
Lewy bodies, Multiple System Atrophy, and Pure Autonomic
Failure, are typiﬁed by the formation of aSyn aggregates. This
has led to the adoption of the term “synucleinopathy” to
describe the group of diseases characterized by pathological
aggregation of aSyn. Interestingly, increased expression of
aSyn has been shown to occur in certain cancers, most
prominently in the skin cancer melanoma (21–23), a cancer
with increased incidence in Parkinson’s Disease patients
(24–29).
aSyn’s roles within the presynaptic terminal have been
extensively explored and multiple speciﬁc functions in regulating chemical neurotransmission within this subcellular
compartment have been described, including modulating
exocytosis (30, 31), endocytosis (32, 33), SNARE complex assembly (34), and vesicle clustering (35–37). Several studies
have shown that aSyn prefers binding highly curved, negatively
charged phospholipid membranes through its N-terminal
domain that associates with the outer leaﬂet of the convexcurved phospholipid bilayer of synaptic vesicles by adopting
a complementary, concave-curved alpha-helical structure
composed of two antiparallel helices (38–40). It is through
these interactions with neurotransmitter vesicles that aSyn is
thought to mediate its presynaptic functions.
In addition to its functions in the presynaptic terminal, aSyn
can also localize to the nucleus where it is less well studied but
has been suggested to modulate several DNA- and RNAdependent processes. These include regulation of histone
modiﬁcation (4, 41), transcription (42, 43), rRNA (44) and
mRNA (45, 46) metabolism. Our recent work also suggests a
J. Biol. Chem. (2022) 298(2) 101552
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Alpha-synuclein bends DNA into circle-like forms
previously unrecognized role for aSyn in modulating DNA
double-strand break (DSB) repair (9). Many of these potential
functions are dependent on aSyn’s ability to bind doublestranded nucleic acids, including DNA. Early work demonstrated that aSyn can bind DNA in its supercoiled form (47)
and that this binding can induce conformational changes both
in the protein, increasing alpha-helical content (48), and in
bound DNA, converting it into an altered B form (48, 49). aSyn
can also directly bind a large subset of DNA promoter sequences (7), including the PGC-1a (42) and Notch (50) gene
promoters, where it appears to often downregulate transcription. NMR spectroscopy demonstrates that the same N-terminal domain that binds curved, negatively charged
phospholipid membranes mediates aSyn’s binding to the
phosphate backbone of DNA (7). Single-molecule techniques
have shown that aSyn binding can stretch DNA and increase
its stiffness (51, 52), while ﬂuorescence resonance energy
transfer (FRET) assays developed to study noncanonical DNA
structures show that aSyn stabilizes intermediate states on the
pathway to DNA hairpin formation (53) and can bind to imotifs (54). Although this work has started to reveal the
mechanism of aSyn binding to DNA, important questions
remain, including the role of potential disease-relevant aSyn
posttranslational modiﬁcations in this process.
Phosphorylation of aSyn at serine-129 (pSyn) is a wellestablished marker of pathological forms of aSyn aggregates.
While <4% of aSyn is phosphorylated at this site in normal
brain, within Lewy bodies >90% of aSyn bears this posttranslational modiﬁcation (55). In addition, human autopsy
studies have shown that pSyn is the most sensitive immunohistochemical marker yet developed to detect Lewy body pathology (56). Although pSyn may be important for disease
pathogenesis, and previous work suggests that aSyn phosphorylation can modulate its nuclear localization (7, 57, 58),
little is known about how this phosphorylation may affect
aSyn’s DNA-binding properties. Our previous work suggested
that both aSyn and pSyn can bind DNA directly, but that
phosphorylation can alter the nature of this interaction in
potentially important ways (9). Given that a detailed understanding of how these two synuclein forms interact with DNA
is still lacking, here we set out to test the properties of DNA
that are important for aSyn binding and how serine-129
phosphorylation could modulate synuclein–DNA interactions.

Results
Alpha-synuclein and S129-phospho alpha-synuclein bind DNA
in a DNA length-dependent manner
Our previous work has shown that both aSyn and pSyn can
bind 300 bp double-stranded DNA, but that aSyn produced
multiple bound states, while pSyn produced only a single
bound state under the conditions tested (9). To better understand this differential binding of aSyn and pSyn to DNA, we
tested the ability of each synuclein to bind DNA of different
lengths. We found that both aSyn and pSyn bind doublestranded DNA in a length-dependent manner (Fig. 1A).
Increasing concentrations of synuclein incubated with a ladder
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containing DNA of various lengths and analyzed using a 10%
polyacrylamide gel electrophoretic mobility shift assay (EMSA)
system demonstrated that both proteins show little obvious
interaction with DNA that is ≤200 bp in length, while longer
DNAs are bound and shifted upward. Close examination of
this shift due to synuclein binding revealed that at a given
synuclein concentration, all DNA lengths above a certain
critical length were bound and shifted upward, while below
this critical length DNA was unbound, and there was no shift
in these bands, and the DNA band in between these two
lengths (at or near the critical length) exhibited both shifted
(bound) and unshifted (unbound) bands (Fig. 1A). The value of
these critical lengths, where the DNA exhibited both shifted
and unshifted bands, decreased with increasing synuclein
concentration. aSyn produced a range of bound states and,
therefore, smearing of the signal at higher DNA lengths
obscured the changes occurring to speciﬁc bands in the aSyn
EMSA. This smearing did not occur with pSyn. This is
consistent with our previous work showing that aSyn binding
to 300 bp DNA produced a laddering effect due to the presence of multiple shifted bound states of different apparent
lengths, while pSyn only produced a single shifted bound state
(9). To understand the DNA length dependence of these band
shifts better, without the complication of multiple-length DNA
fragments in the same lane, we performed similar EMSAs
using DNA of only a single length, ranging from 125 to 500 bp.
These experiments also showed a clear length dependence to
aSyn and pSyn DNA binding, with aSyn binding DNA better
than pSyn at DNA lengths between 125 and 300 bp (Fig. 1B).
The Hill slopes for binding of aSyn and pSyn were both positive, suggesting cooperative binding interactions between both
synuclein forms and DNA, although we did not detect significant differences in the amount of cooperativity between aSyn
or pSyn binding DNA. Given the relative simplicity of interpreting mobility changes with pSyn, due to the lack of
smearing at high apparent DNA lengths, we also tested the
ability of pSyn to shift ladder DNA under different gel conditions. We saw similar upward shifts of all DNA fragments
above a certain critical length, no change below this critical
length, and partial binding at or near these critical lengths
when performing EMSAs with polyacrylamide gel concentrations ranging between 6 and 20% (Fig. S1A). To assay binding
of aSyn to 300 bp DNA using another parallel technique to
EMSA, we performed atomic force microscopy (AFM) on
surfaces where DNA was applied either without aSyn or in the
presence of 57 μM aSyn, a concentration where we measure
robust aSyn-DNA binding in our EMSA experiments. These
AFM data show evidence of increased apparent DNA thickness and a globular protein signal bound to 300 bp DNA in the
condition where aSyn is present (Fig. S1B), suggesting that
aSyn does bind 300 bp double-stranded DNA, as previous
AFM studies have shown with longer DNA molecules (51).
The physiologically and pathologically relevant conformations of aSyn are subject to debate, and questions remain about
the role/s of the unfolded monomeric state (59, 60), as well as a
tetrameric structure that it can also form (61). Its ability to
bind DNA resides in the N-terminal portion of the protein,
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Figure 1. Alpha-synuclein and phospho-synuclein bind DNA in a DNA length-dependent manner. A, top, EMSA with increasing alpha-synuclein (aSyn)
and serine-129 phosphorylated alpha-synuclein (pSyn) concentrations with DNA of different lengths shows an upward shift of DNA bands greater than
200 bp at higher synuclein concentrations. Shifts produced by aSyn and pSyn of speciﬁc bands (within gray rectangles) are enlarged and shown below.
Bottom, larger image of aSyn and pSyn EMSA shows upward shift of speciﬁc DNA bands longer than 200 bp depending on aSyn or pSyn concentration. For
example, at 57 μM pSyn the 300 bp band exhibits both shifted (green arrow) and unshifted (blue arrow) species compared with the 4 μM concentration,
where only an unshifted band (blue arrow) is present. B, top, shifts produced by aSyn (left) and pSyn (right) with individual DNA lengths (125, 200, 300, 400,
and 500 bp). Bottom, group data show the fraction of different length DNAs shifted by 57 μM aSyn or pSyn. Both aSyn and pSyn binding to DNA depends
on DNA length (aSyn EL50 = 153 bp, R2 = 0.986, deviation from zero slope p < 0.0001, Hill slope = 3.1; pSyn EL50 = 281 bp, R2 = 0.991, deviation from zero
slope p < 0.0001, Hill slope = 6.0; four-parameter dose-response curve; N = 3 gels). aSyn produces more shift than pSyn of 125, 200 and 300 bp DNA (shifted
fraction: aSyn-125 bp = 0.327 ± 0.015, pSyn = 125 bp = 0.007 ± 0.012, unpaired t test p < 0.0001; aSyn-200 bp = 0.740 ± 0.010, pSyn = 200 bp = 0.120 ±
0.104, unpaired t test p = 0.0005; aSyn-300 bp = 0.803 ± 0.025, pSyn = 300 bp = 0.617 ± 0.050, unpaired t test p = 0.0045; aSyn-400 bp = 0.947 ± 0.012,
pSyn = 400 bp = 0.927 ± 0.015, unpaired t test p = 0.145; aSyn-500 bp = 1.000 ± 0.000, pSyn = 500 bp = 1.000 ± 0.000; N = 3 gels). Points at 0 DNA length set
to 0.0 shifted fraction based on model for ﬁtting purposes. EMSA, electrophoretic mobility shift assay.

and previous studies have noted the importance of electrostatic interactions between positively charged lysine residues in
the N-terminal domain and the phosphate groups within the
DNA backbone (7). This is the same N-terminal region that
binds curved, negatively charged phospholipid membranes by
adopting a discontinuous alpha-helical structure containing
two antiparallel curved helices (38–40). The longest of these
alpha-helices is made up of 48 amino acids (residues 45–92)
and is measured to be less than 5 nm in length (40). In
contrast, a 100 bp double-stranded DNA molecule is 34 nm,
seven times longer than the DNA-binding domain of aSyn.
These estimates and our data suggest that the length dependence of synuclein–DNA binding is not simply due to physical
constraints preventing binding to shorter-length DNAs.
Alpha-synuclein and S129-phospho alpha-synuclein bind DNA
with blunt or 50 overhanging ends with similar afﬁnity
We next tested the effect of DNA end structure on aSyn and
pSyn binding. We used 300 bp DNA with either a blunt terminus on both ends or a 300 bp DNA with a 4 base 50 overhang on each end. In our 10% polyacrylamide gel EMSA
condition, both aSyn and pSyn bound these 300 bp DNAs

similarly (Fig. 2). This suggests that the nature of the DNA end
does not strongly inﬂuence aSyn and pSyn binding and that
synuclein may not be a DNA end-binding protein, but rather a
protein that binds DNA along its length, potentially in its
major or minor groove. Similarly, changing the sequence of
DNA, varying GC content from 56 to 67%, while keeping the
length 300 bp, had no signiﬁcant effect on the amount of or
cooperativity of aSyn binding (Fig. S2A). Varying Tris concentration between 5 and 30 mM similarly also had no signiﬁcant effects on the amount of or cooperativity of aSyn
binding (Fig. S2B). These data suggest that synuclein is not
recognizing very speciﬁc DNA sequences when binding, rather
other aspects of the DNA molecule, such as stiffness or ability
to adopt non-B forms, may be important. These more global
DNA properties can be inﬂuenced by sequence, but our data
suggest that aSyn and pSyn binding does not have a tight
speciﬁcity for one particular DNA sequence. In our experiments, we only varied 300 bp DNA GC content between 56
and 67%, while previous work has shown that aSyn does bind
16 bp DNA sequences containing 100% GC content tightly and
in the process can change them from B-form to an altered Bform of DNA (49). Our data are potentially consistent with this
previous result (49), since only lower GC content sequences
J. Biol. Chem. (2022) 298(2) 101552
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Figure 2. Alpha-synuclein and phospho-synuclein bind DNA with blunt or 50 overhanging ends with similar afﬁnity. Alpha-synuclein (aSyn, A) and
serine-129 phosphorylated alpha-synuclein (pSyn, B) bind 300 bp DNA with blunt or 300 bp DNA with a 4 base 50 overhanging end on both sides similarly
(shifted fraction blunt end at 0–4, 16, 29, and 57 μM aSyn: 0.000 ± 0.000, 0.007 ± 0.012, 0.387 ± 0.110, 0.857 ± 0.006; shifted fraction overhanging ends at
0–14, 29 and 57 μM aSyn: 0.000 ± 0.000, 0.417 ± 0.121, 0.917 ± 0.031; comparison of shifted fraction of blunt and overhanging end DNA for each aSyn
concentration by paired t test shows no signiﬁcant differences, p between 0.059 and 0.423; variable slope dose-normalized response curve; N = 3 gels, x-axis
aSyn concentration on log scale; shifted fraction blunt end at 0–14, 29 and 57 μM pSyn: 0.000 ± 0.000, 0.250 ± 0.098, 0.607 ± 0.101; shifted fraction
overhanging ends at 0–14, 29 and 57 μM pSyn: 0.000 ± 0.000, 0.217 ± 0.188, 0.573 ± 0.161; comparison shifted fraction of blunt and overhanging end DNA
for each pSyn concentration by paired t test shows no signiﬁcant differences, p between 0.469 and 0.604; variable slope dose-normalized response curve;
N = 3 gels, x-axis pSyn concentration on log scale).

(56–67%) were tested, and it will be interesting in the future to
explore the effects of wider ranges of GC content on
synuclein–DNA binding. To test the importance of potential
electrostatic interactions between aSyn and DNA in the
binding reaction, the ionic strength of the composition of our
EMSA buffer was increased. This was done by adding
increasing amounts of the divalent cation Ca2+ to minimize the
effect of osmolarity changes compared with a monovalent
cation of comparable ionic strength. In these experiments,
high concentrations of Ca2+, around 25 mM, did signiﬁcantly
decrease aSyn–DNA binding (Fig. S3). This potentially indicates the importance of electrostatic interactions between
aSyn’s positively charged N-terminal domain and the negatively charged phosphate backbone of DNA for this binding.
Alpha-synuclein and S129-phospho alpha-synuclein binding
to DNA is facilitated by small molecules that bind in the minor
groove but not the major groove
To understand how aSyn and pSyn interact with doublestranded DNA, EMSAs under conditions where either the
minor groove-binding small-molecule Hoechst 33258 or the
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major groove binder methyl green was present were performed. Samples were tested for possible interactions between
Hoechst and the intercalating Sybr Gold ﬂuorescent dye used
to image DNA. Hoechst 33258 at concentrations from 0 to
16 μM had no appreciable effect on Sybr Gold ﬂuorescence
from 300 bp DNA (Fig. 3A). The addition of either aSyn or
pSyn showed increased binding of the respective synuclein to
DNA in a Hoechst 33258 dose-dependent manner, as evidenced by an increased fraction of shifted DNA (Fig. 3A). In
contrast to the minor groove binder Hoechst 33258, the major
groove-binding small-molecule methyl green reduced ﬂuorescence from Sybr Gold at higher concentrations, with no
appreciable effect between 0 and 25 nM, but a large reduction
at 500 nM, and the abolition of Sybr Gold ﬂuorescence at 1 μM
(Fig. 3B). The addition of aSyn resulted in no increase in the
fraction of shifted DNA at methyl green concentrations between 0 and 25 nM, indicating that methyl green does not
promote aSyn-DNA binding (Fig. 3B). Between 250 and
500 nM, we did not quantify aSyn-DNA binding given the
complication that methyl green reduces Sybr Gold ﬂuorescence at these concentrations. However, it was observed that
aSyn competes with methyl green and substantially restores
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Figure 3. Alpha-synuclein and phospho-synuclein DNA binding is increased by the minor groove-binding agent Hoechst 33258 and competes with
the major groove-binding agent methyl green. A, increasing concentrations of the DNA minor groove binder Hoechst 33258 (0–16 μM) does not change
the signal generated by DNA (left side of each gel) but does increase shifted fraction caused by 14 μM alpha-synuclein (aSyn) and serine-129 phosphorylated
alpha-synuclein (pSyn; aSyn Hoechst EC50 = 21.29 μM, R2 = 0.653, deviation from zero slope p = 0.0003, three-parameter dose–response curve; N = 4 gels;
pSyn Hoechst EC50 = 12.76 μM, R2 = 0.395, deviation from zero slope p = 0.0002, x-axis Hoechst concentration on log scale). B, in contrast, high concentrations (at 500 nM and above) of the DNA major groove binder methyl green decrease intercalation and/or ﬂuorescence of the Sybr dye used to image
DNA (left side of aSyn and pSyn gels). Addition of 29 μM aSyn or pSyn competes with methyl green and partially restores Sybr dye ﬂuorescence signal.
Methyl green does not affect the shifted fraction of DNA in the presence of 29 μM aSyn or pSyn at values where it does not reduce Sybr dye ﬂuorescence (at
250 nM and less, aSyn: R2 = 0.205, deviation from zero slope p = 0.5473; pSyn: R2 = 0.748, deviation from zero slope p = 0.1351; N = 3 gels, x-axis methyl
green concentration on log scale). The 14 and 29 μM aSyn and pSyn concentrations were chosen since these produced intermediate levels of shift, allowing
for detection of possible changes with small-molecule dye addition.

Sybr Gold DNA ﬂuorescence at these higher methyl green
concentrations (Fig. 3B). Similar results were also seen with
pSyn with evidence that pSyn was able to compete with methyl
green even more effectively than aSyn to restore Sybr Gold
DNA ﬂuorescence (Fig. 3B).
These data suggest that the minor groove-binding agent
Hoechst 33258 can alter the physical properties of DNA in a
way that can promote aSyn and pSyn binding. Previous work
has suggested that Hoeschst 33258, a bisbenzimide minor
groove-binding molecule, can bend DNA upon binding
(62, 63), potentially indicating that the ability of Hoechst 33258
to increase aSyn and pSyn DNA binding is related to a preference of synuclein for bent DNA conformations. In addition,
the competitive interaction between the major groove binder
methyl green (and not with the minor groove binder Hoechst
33258) with aSyn and pSyn suggests that synuclein itself is
binding DNA within the major groove and not the minor
groove. While the exact binding mechanism of Sybr Gold has
not been extensively studied, this dye and other members of
the class intercalate between base pairs (64). Our data suggest
that methyl green (at higher concentrations) blocks Sybr Gold
intercalation between base pairs, either by direct steric hindrance or by altering the parallel base-stacking interactions
that are required for Sybr Gold intercalation. Increasing concentration of aSyn and pSyn appears to compete with methyl

green binding to the major groove without altering Sybr Gold
intercalation.
Altering DNA concentration, while keeping alpha-synuclein
concentration ﬁxed, changes the nature of the bound
complex, but this change does not happen with S129-phospho
alpha-synuclein
To understand the differing nature of the bound state/s
between aSyn or pSyn with DNA, we performed a set of experiments where aSyn concentration was ﬁxed at 57 μM and
the DNA concentration was varied between 0.1 and 200 nM.
At higher DNA concentrations (20–200 nM), most DNA
signals were found in either the unbound band running at its
true 300 bp length or in a single discrete shifted band, indicating a single bound state running at an apparent length of
600 bp (Fig. 4A). At intermediate DNA concentrations
(2–10 nM), the unbound band was not detectable, and all
signal was either in the discrete band at 600 bp or in a smear
of higher apparent lengths (Fig. 4A). At the lowest DNA
concentrations (0.1–1 nM), all the signals appeared in a single,
discrete high apparent length band running at >1517 bp
(Fig. 4A). In contrast to the aSyn data, with pSyn there was no
change in the pattern of binding at any tested DNA concentration (0.1–200 nM). At all concentrations, 60% of the DNA
J. Biol. Chem. (2022) 298(2) 101552
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Figure 4. Lowering DNA concentration shifts alpha-synuclein-bound complexes into a different state, but this does not happen with phosphosynuclein. A1, decreasing 300 bp DNA concentration from 200 nM to 0.1 nM with ﬁxed alpha-synuclein (aSyn) concentration (57 μM) produces a change in
the apparent length of the complex from to a lower value shift (running 600 bp, green arrow) to a higher value shift (running >1517 bp DNA, red arrow).
Unshifted (unbound) DNA marked by the blue arrow. A2, Western blot showing aSyn protein loaded into each lane. A3, DNA gel (green) and aSyn Western
blot (red) localization from the same experiment. A4, left, group data showing total shifted fraction as a function of DNA concentration (DNA IC50 =
72.24 nM, R2 = 0.919, three-parameter dose–response curve, N = 3 gels). Right, shifted fraction of high (>1517 bp) and low (600 bp) apparent length
complexes (high length complex DNA IC50 = 16.26 nM, R2 = 0.961, three-parameter dose–response curve, N = 2 gels; low length complex DNA EC50 =
5.90 nM, R2 = 0.842, three-parameter dose–response curve, N = 2 gels). x-axis DNA concentrations on a log scale. B1, decreasing 300 bp DNA concentration
from 200 nM to 0.1 nM with ﬁxed serine-129 phosphorylated alpha-synuclein (pSyn) concentration (57 μM) produces no change in the apparent length of
the bound complex (running 500 bp, green arrow). Unshifted (unbound) DNA marked by the blue arrow. B2, Western blot showing pSyn protein loaded
into each lane. B3, DNA gel (green) and pSyn Western blot (red) localization from the same experiment. B4, left, group data showing little change in total
shifted fraction as a function of DNA concentration (DNA EC50 = 0.38 nM, R2 = 0.116, three-parameter dose–response curve, N = 3–4 gels). Right, shifted
fraction of each complex shows no detectable high (>1517 bp), and only detectable low (500 bp) apparent length complexes. x-axis DNA concentrations
on a log scale.

signal was in a single, discrete unshifted (unbound) band
running at 300 bp, and the other 40% was present in a single
shifted (bound) band running at 500 bp (Fig. 4B).
Altering protein concentration, while keeping DNA
concentration ﬁxed, changes the nature of the bound complex
with alpha-synuclein, but this does not happen with
S129-phospho alpha-synuclein
We next performed a set of experiments where synuclein
protein concentration was varied between 0 and 57 μM, while
DNA concentration was ﬁxed at either a relatively low
(0.1 nM) or intermediate (6 nM) concentration. In these experiments, aSyn-DNA binding once again exhibited a range of
bound states limited on the lower end by a discrete state
running at 600 bp, favored at the higher DNA concentration
(6 nM) when aSyn concentration was relatively low (2–29 μM)
—a low aSyn-to-DNA ratio (Fig. 5A). While at a high aSyn-toDNA ratio, when DNA was at the lower concentration
(0.1 nM) and aSyn was relatively high (43–57 μM), a single
larger discrete state was favored, running at >1517 bp
(Fig. 5A). At intermediate aSyn-to-DNA ratios, a range of
bound states between these two limits was observed (Fig. 5A).
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Once again, this range of states was not observed with pSyn,
and conditions varying pSyn produced only a single bound
state running at 500 bp at high pSyn concentrations
(29–57 μM, Fig. 5B).
Only alpha-synuclein, and not S129-phospho alpha-synuclein,
binds circular DNA
Our results varying either DNA or protein concentration,
while keeping the other ﬁxed (Figs. 4 and 5), are consistent
with a model where aSyn and pSyn are both able to bind DNA
in at least one state, which shifts the mobility of the bound
complex to run as a discrete band at an apparent length of
500 to 600 bp. Over the DNA concentration range tested
(0.1–200 nM) for both synuclein proteins, this single bound
state is the only complex formed with pSyn. aSyn, however,
produces multiple bound states. This range of aSyn-DNA
complexes occurs, however, over a speciﬁc interval when using 300 bp DNA. High DNA concentrations (20–200 nM)
favor a single discrete state that runs at an apparent length of
600 bp, while low DNA concentrations (0.1–1 nM) favor a
much higher, but still single discrete state, at an apparent
length >1517 bp. At intermediate DNA concentrations
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Figure 5. Increasing alpha-synuclein concentration shifts alpha-synuclein-bound complexes into a different state, but this does not happen with
phospho-synuclein. A1, decreasing alpha-synuclein (aSyn) protein concentration from 57 to 1 μM with 300 bp DNA concentration ﬁxed at either 0.1 nM
(left) or 6 nM (right) produces a change in the apparent length of the complex from a higher value shift (running >1517 bp DNA, red arrow) to a lower value
shift (running 600 bp, green arrow). Unshifted (unbound) DNA marked by the blue arrow. A2, Western blot showing aSyn protein loaded into each lane. A3,
DNA gel (green) and aSyn Western blot protein (red) localization from the same experiment. A4, group data showing shifted fraction as a function of aSyn
concentration for the two different ﬁxed DNA concentrations. The low DNA concentration curve is left-shifted (aSyn EC50: low DNA conc. = 0.273 μM, R2 =
0.619; high DNA conc.=5.846 μM, R2 = 0.977, three-parameter dose–response curve; N = 3–4 gels, x-axis aSyn concentration on log scale). B1, decreasing
serine-129 phosphorylated alpha-synuclein (pSyn) protein concentration from 57 to 1 μM with 300 bp DNA concentration ﬁxed at either 0.1 nM (left) or
6 nM (right) produces only a complex with an apparent length of 500 bp (green arrow) at the higher pSyn concentrations. Unshifted (unbound) DNA
marked by the blue arrow. B2, Western blot showing pSyn protein loaded into each lane. B3, DNA gel (green) and pSyn Western blot (red) localization from
the same experiment. B4, group data showing a similar shifted fraction as a function of pSyn concentration for the two different ﬁxed DNA concentrations
(pSyn EC50: low DNA conc.=27.34 μM, R2 = 0.779; high DNA conc.=32.49 μM, R2 = 0.981, four-parameter dose–response curve; N = 3 gels, x-axis pSyn
concentration on log scale).

(2–10 nM), a variety of aSyn-DNA bound states are present
that span this range (600 to >1517 bp). These data suggest a
model where pSyn can bind DNA as a single monomer (or
potentially small multimer) to the DNA molecule, but that
only one such binding event occurs per DNA molecule. In
contrast, aSyn can make a similar one-synuclein-to-one DNA
molecular complex and that is favored at relatively high DNA
concentrations, but when DNA concentrations are relatively
low, multiple monomers (or small multimers) bind as discrete
events along the DNA length. Consistent with this, there is a
saturation of aSyn-DNA binding, presumably when all possible
sites on a single molecule of DNA are occupied to create the
largest possible bound complex (running at >1517 bp). Our
results are similar to previous work using atomic force microscopy to image aSyn binding to linear 1000 bp DNA molecules, where at lower aSyn concentration (0.1 μM), aSyn
molecules bind at discrete sites randomly distributed up and
down the DNA molecule. At a higher aSyn concentration
(40 μM), however, the entire DNA molecule was evenly coated
with a single layer of aSyn (51). In our experiments, at high
aSyn-to-DNA ratios, the data are also consistent with an
increasing number of aSyn molecules binding one DNA

molecule up to a saturation point. aSyn binding signiﬁcantly
changes the conformation of DNA so that it runs at a much
higher apparent length (>1517 bp). This suggests that aSyn
may be bending DNA into speciﬁc shapes, potentially circlelike forms, which are known to run much more slowly
through polyacrylamide gels (65). This kind of bending reaction upon binding is inhibited by phosphorylation at serine129 in pSyn, since even at high pSyn-to-DNA ratios pSyn
binds DNA in a one-to-one fashion that does not further slow
its migration through the polyacrylamide gel.
Given our data suggesting that synuclein proteins promote
DNA bending upon binding (Fig. 3) and that multiple aSyn
molecules may bend a single DNA molecule into a circle-like
form (Figs. 4 and 5), we next tested whether synuclein proteins
bind to circular DNA molecules that are forced by their topology into a bent conformation. We converted the linear
300 bp DNA (with four base overhangs on each end) used in
our previous experiments into a 304 bp circular form using T4
ligase, both in the presence and absence of the DNA bending
protein HMGB1 (Fig. 6, A and B). To remove any remaining
linear DNA and conﬁrm their circular state, we incubated this
product with either T5 or T7 exonuclease. These data
J. Biol. Chem. (2022) 298(2) 101552
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Figure 6. Alpha-synuclein binds 304 bp circular DNA forms and phospho-synuclein does not. A, agarose gel electrophoresis shows 300 bp linear DNA
(with additional 4 base 50 overhanging ends on each side) treated with no T4 ligase, T4 ligase, or T4 ligase and the DNA bending protein HMGB1. The
untreated sample only contains 300 bp linear DNA. The T4 ligase treated sample contains 300 bp and 604 bp linear DNA and 304 bp circular forms (which
run faster than their linear counterpart in the agarose gel system). The sample treated with T4 ligase and HMGB1 shows increased formation of 304 bp
circular DNA forms. B, polyacrylamide (6%) gel electrophoresis shows 300 bp linear DNA treated with no T4 ligase, T4 ligase, or T4 ligase and the DNA
bending protein HMGB1. The untreated sample only contains 300 bp linear DNA. The T4 ligase treated sample contains 300 bp & 604 bp linear DNA and
300 bp circular forms (which run slower than their linear counterpart in the polyacrylamide gel system). The sample treated with T4 ligase and HMGB1
shows the formation of a new 304 bp circular DNA topoisomer form (which runs somewhat faster due to its more compact nature). C, 300 bp linear DNA
ﬁrst treated with T4 ligase and HMGB1 (to produce some circular forms, as in B), then with either T7 or T5 exonuclease to remove linear DNA molecules,
shows the expected resistance to exonuclease treatment of the 304 bp circular DNA forms. D, top, negative stain transmission electron microscopy of
300 bp linear DNA without ligase treatment shows linear molecules of the expected length (100 nm). Scale bar 25 nm. Bottom, linear DNA treated with T4
ligase shows 304 bp circular molecules with the expected diameter (30 nm). Scale bar 25 nm. E, only aSyn, and not pSyn, causes a shift of the 304 bp
circular DNA forms created in the presence of HMGB1 (red arrows: circular form, orange arrows: circular topoisomer) to a higher apparent length (purple
arrow). F, left, synuclein concentration dependence of shift of circular DNA forms created in the presence of HMGB1 shows that only aSyn causes a shift at
these concentrations and pSyn does not. Right, group data showing shifted fraction of 304 bp DNA circles and circular topoisomers as a function of
synuclein concentration (aSyn: EC50 circular DNA = 1.608 μM, R2 = 0.967; EC50 circular DNA topoisomer = 1.637 μM, R2 = 0.993; pSyn: EC50 circular &
circular DNA topoisomer undeﬁned; at 3–57 μM one-way ANOVA for each concentration, p between <0.0001 and 0.0079; post-hoc Tukey tests shows no
signiﬁcant differences between two [circle versus topoisomer] aSyn conditions p between 0.453 and 0.960, and two [circle versus topoisomer] pSyn conditions p = 0.252–0.956; there are signiﬁcant differences between two [aSyn versus pSyn] circle conditions p = 0.001–0.028, and the two [aSyn versus pSyn]
topoisomer conditions p ≤ 0.0001–0.002; three-parameter dose–response curve, N = 3 gels, x-axis synuclein concentrations on log scale).

demonstrate the formation of 304 bp circular DNA, including
an additional speciﬁc topoisomer that was only present when
circular DNA, was formed in the presence of HMGB1 (Fig. 6,
B and C). To further check the circular nature of these DNA,
we performed negative stain transmission electron microscopy
on the linear and circular DNA samples. These data show the
expected presence of linear and circular forms in their
respective samples (Fig. 6D). These circular forms run in a
polyacrylamide gel system at a high apparent length
(>1517 bp), consistent with previous work showing that circular DNA is much less mobile than its linear counterpart in
polyacrylamide gels and that circular topoisomers are more
compact and therefore migrate somewhat faster than topologically simple circles (65). Interestingly, incubation of these
304 bp circular forms with aSyn produced clear evidence of
binding, with a shift of both the circular and circular topoisomer DNA bands (Fig. 6, E and F), and shift of the simple
circular DNA form created without the presence of HMGB1
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(Fig. S4). pSyn was unable to bind either of these circular forms
and produced no appreciable shift (Figs. 6, E and F and S4).
These data suggest that the high apparent length complex
formed by aSyn binding to linear DNA under conditions that
favor this bound state (high aSyn-to-DNA ratio, Figs. 4A and
5A) may be similar in conformation to circular DNA bound to
aSyn, since their bound complexes share similar properties,
including apparent length, and binding dependence on aSyn
concentration (Fig. 6F).
Mutant alpha-synuclein and beta- and gamma-synuclein do
not bind linear DNA similarly to wild-type alpha-synuclein
To determine the potential effects of mutations in aSyn on
300 bp linear DNA binding, we tested under similar conditions, three disease-causing point mutations (A30P, E46K,
A53T) and a deletion form where the central nonamyloid betacomponent (NAC) domain, which is important for ﬁbrillar
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aggregation of the protein, was removed (delta NAC). We
tested all proteins at a low DNA concentration (1.3 nM), which
shows moderate levels of binding when aSyn is used (Fig. 7A).
All mutant forms of aSyn were capable of binding and shifting
DNA, although with different efﬁciencies and to different
apparent lengths. Two of the disease-causing point mutations
(A30P, A53T) were less efﬁcient at binding DNA than wildtype (WT) but did shift DNA to a similar apparent length,
while the other disease-causing point mutation tested (E46K)
was more efﬁcient at binding DNA and shifted it to a higher
apparent length (Fig. 7A). The delta NAC form was also more
efﬁcient at binding DNA but shifted it to a lower apparent
length than WT (Fig. 7A).
To test the ability of the two aSyn paralogs, beta- and
gamma-synuclein (bSyn and gSyn, respectively), to bind DNA
we next tested all three synuclein proteins under similar

conditions. We tested all three proteins at an intermediate
DNA concentration (4 nM), which shows clear binding when
aSyn is used (Fig. 7B). Unlike aSyn, however, we did not detect
appreciable binding of either bSyn or gSyn to DNA (Fig. 7B).
We next wanted to test the effect of lowering DNA or bSyn
concentration on potential binding between these two molecules. Interestingly, lowering DNA concentration (0.2–4 nM)
while keeping bSyn concentration ﬁxed (57 μM) showed no
obvious change at the higher DNA concentrations, but at the
lower DNA concentrations, the DNA signal was reduced so
that at the lowest DNA concentration (0.2 nM, highest bSynto-DNA ratio), no DNA signal could be detected at all
(Fig. S5A). A similar phenomenon was seen when DNA concentration was ﬁxed at 0.2 nM and bSyn concentration varied
(3–57 μM), where at the highest bSyn-to-DNA ratio, DNA
signal was absent (Fig. S5B). A similar set of results was also
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Figure 7. Mutant alpha-synuclein and beta- and gamma-synuclein do not bind DNA like wild-type alpha-synuclein. A1, left, increasing concentrations
of wild-type (WT) alpha-synuclein (aSyn) and disease-causing point mutations (A30P, E46K, A53T) shift 300 bp DNA to higher apparent lengths, with A30P
and A53T aSyn being less efﬁcient at shifting than WT, and E46K being more efﬁcient and shifting to a higher apparent length than WT. Right, deletion of
the central aggregation-prone NAC domain of aSyn (deltaNAC) increases the efﬁciency of shifting but reduces the apparent length of the shifted species
compared to WT. A2, Coomassie stain showing aSyn proteins loaded into each lane. A3, DNA gel (green) and Coomassie stain (red) localization from the same
experiment. A4, group data showing shifted fraction as a function of aSyn concentration (aSyn R2: WT = 0.980, A30P = 0.963, E46K = 0.999, A53T = 0.965;
shifted fraction 1.4 μM aSyn: WT = 0.550 ± 0.082, A30P = 0.270 ± 0.047, E46K = 0.975 ± 0.028, A53T = 0.379 ± 0.102; shifted fraction 2.9 μM aSyn:
WT = 0.743 ± 0.049, A30P = 0.515 ± 0.074, E46K = 0.996 ± 0.007, A53T = 0.611 ± 0.010; at 1.4 μM one-way ANOVA p < 0.0001; post-hoc Tukey tests WT versus
A30P, E46K, A53T all p between 0.0002 and 0.0449; at 2.9 μM one-way ANOVA p < 0.0001; post-hoc Tukey tests WT versus A30P, E46K, A53T all p between
0.0004 and 0.0174; shifted fraction 1.4 μM aSyn: WT = 0.597 ± 0.148, deltaNAC = 1.000 ± 0.000; shifted fraction 2.9 μM aSyn: WT = 0.764 ± 0.113, deltaNAC =
1.000 ± 0.000; at 1.4 μM t test p = 0.0092; at 2.9 μM t test p = 0.0225; three-parameter dose–response curve; N = 3 gels, x-axis aSyn concentrations on log
scale). B1, increasing aSyn concentration produces a shift of 300 bp DNA to an apparent length of 600 bp, while beta-synuclein (bSyn) and gammasynuclein (gSyn) produce no such shift. B2, Coomassie stain showing synuclein proteins loaded into each lane. B3, DNA gel (green) and Coomassie stain
(red) localization from the same experiment. B4, group data showing shifted fraction as a function of synuclein concentration (aSyn R2 = 0.791; shifted
fraction: 29 μM aSyn = 0.039 ± 0.020, 57 μM aSyn = 0.199 ± 0.066, all other values including for all bSyn and gSyn concentrations produced an undetectable
shift = 0.0; at 29 μM one-way ANOVA p = 0.0087; post-hoc Tukey test aSyn versus bSyn, and aSyn versus gSyn p = 0.0139; at 57 μM one-way ANOVA
p = 0.0010; post-hoc Tukey test aSyn versus bSyn, and aSyn versus gSyn p = 0.0017; three-parameter dose–response curve; N = 3 gels, x-axis Syn concentrations on log scale).
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obtained when testing the ability of gSyn to bind DNA
(Fig. S6), where the highest gSyn-to-DNA ratios produced a
loss of DNA signal. The physical interpretation of this loss in
DNA signal when either bSyn or gSyn is present at a high Synto-DNA ratio is not clear. There is no evidence that this is due
to either DNA trapped in the well or DNA migrating at a
much faster speed under these conditions (data not shown).
This suggests that bSyn and gSyn may be changing the
conformation of DNA in a way that prevents the Sybr Gold
ﬂuorescence used to detect DNA, potentially by directly
inhibiting Sybr Gold intercalation into B form DNA or by
altering the DNA from a B form to another non-B form that
Sybr Gold does not bind, as has been previously suggested to
occur when synuclein binds DNA (48, 49). Another possibility
is that bSyn and gSyn could be degrading DNA via a nuclease
function. It has been shown that oxidized aSyn species can act
as nucleases (66), although in our experiments we do not
detect evidence of the DNA degradation that would be expected in this case and have also chelated the divalent metal
ions required for many nucleases to function.

Discussion
Our data show that both aSyn and pSyn can bind DNA, but
do so in a DNA length-dependent manner. DNA molecules
shorter than 300 bp are not signiﬁcantly bound under the
conditions tested, while DNA longer than this is bound and
shifted in our EMSA assay. Interestingly, DNA that is 300 bp
long is often only partially bound, producing discrete unshifted
(unbound) and shifted (bound) bands. DNA sequence or end
structure does not strongly modulate this binding, arguing that
another length-dependent physical property of DNA is
important for binding. One potential possibility is DNA stiffness. Previous work has shown that DNA >300 bp in length is
ﬂexible enough to easily bend into a circular form, while DNA
<200 bp does not easily form circles without the use of speciﬁc
DNA bending proteins because of its inherent stiffness (67).
DNA that is 200 to 300 bp long is at a length (and stiffness)
where unaided circle formation starts to be possible. This
suggests that the interaction of aSyn and pSyn with DNA may
be modulated by DNA stiffness in such a way that binding
requires a structural change in DNA that cannot occur when it
is too stiff. Such a structural change could involve DNA
bending and our data using the bisbenzimide DNA dye
Hoechst 33258, a dye known to bend DNA (62, 63), suggests
that DNA bending promotes aSyn and pSyn binding. aSyn is
able at high aSyn-to-DNA ratios to produce a structurally
different complex than at low aSyn-to-DNA ratios. Our data
suggest that this complex may involve multiple aSyn monomers or multimers binding DNA until all possible sites are
occupied. The fully saturated complex runs at a much higher
apparent length and may involve DNA bending into a circlelike state. Serine-129 phosphorylation strongly inhibits the
formation of this potential circle-like form, and our experiments testing aSyn and pSyn binding directly to 304 bp circular DNA are consistent with this interpretation. bSyn and
gSyn do not bind DNA similarly to aSyn under the conditions
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we have used. These data suggest that aSyn has unique
properties among the synuclein family members in terms of its
ability to bind DNA and stabilize circle-like forms. It also
suggests that serine-129 phosphorylation is a potential regulatory switch that can inhibit this process. Interestingly, known
disease-relevant point mutations in alpha-synuclein modulate
DNA binding in complicated ways, with A30P and A53T
reducing binding and E46K increasing binding. Removal of the
NAC domain also increases DNA binding, but produces a state
with a lower apparent length.
It strikes us that 200 to 300 bp DNA when bent into a circle
has a diameter that is 20 to 30 nm. This is similar to the
diameter of a synaptic vesicle found at the nerve terminal to
which aSyn is known to bind (1–3). Several studies have shown
that aSyn binds synaptic vesicles through its N-terminal
domain, which can form two concave-curved antiparallel
alpha-helices that associate with the convex-curved outer
leaﬂet of the vesicle lipid bilayer (38–40). This highly curved
phospholipid bilayer of a 20 to 40 nm (in diameter) synaptic
vesicle is thought to present a geometry that strongly favors
aSyn binding, compared with other membranous compartments found in the terminal that have less curved geometries.
The concave-curved antiparallel alpha-helices in aSyn’s
N-terminus are amphipathic, favoring strong interactions between their hydrophobic face and the lipid environment within
the membrane and between the 12 positively charged lysine
residues found on the opposite face (between amino acids
1–80) and the membrane’s negatively charged phosphate head
groups. Previous work using NMR spectroscopy has shown
that aSyn binds DNA by interacting with the phosphate
backbone, using the same N-terminal region that binds curved
phospholipid membranes (7). Given the comparable geometries of a 200 to 300 bp long DNA molecule bent into a circle
and a synaptic vesicle, this suggests to us that aSyn may have
evolved to bind negatively charged convex surfaces of discrete
geometries using its N-terminal domain and does so with both
synaptic vesicles and DNA in a similar fashion. Using structural data taken from aSyn bound to micelles (composed of
70:30 mixtures of dodecyl phosphocholine:sodium dodecylsulfate) (40) to make a docking model with double-stranded
DNA suggests that each N-terminal antiparallel alpha-helix
can ﬁt within a major groove so that two consecutive major
grooves of DNA are occupied. This model positions aSyn’s
hydrophobic helix face close to individual DNA bases and also
positions several helix lysine residues within proximity of the
DNA phosphate backbone, allowing for possible electrostatic
interactions with the DNA phosphate backbone (Fig. 8, A and
B, S7 and S8). At the presynaptic terminal, aSyn’s binding to
negatively charged, curved phospholipid surfaces is important
for modulating synaptic vesicle cycling and neurotransmission
(30–34), while in the nucleus it could be important for
modulating DNA structure-dependent processes where aSyn
has been implicated, such as transcription (42, 43) and DSB
repair (9). It will be important in the future to test this model
in both DNA and spherical phospholipid bilayer systems that
present negatively charged curved surfaces of the appropriate
geometry to determine the details of alpha-synuclein binding
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Figure 8. Model of alpha-synuclein binding to double-stranded DNA and the potential similarities between this DNA binding and binding to
phospholipid vesicles. A, single image from an animation (see Fig. S7 for full animation) showing a model of aSyn bound to DNA. The aSyn coordinates
come from previous work showing its structure bound to a phospholipid micelle (40). The two curved alpha-helices of the N-terminal domain of aSyn ﬁt into
consecutive major grooves of B form DNA. Lysine residues within the protein are labeled. The C-terminal domain, containing the serine-129 phosphorylation site, is poorly resolved in previous structural work, so it is not clear how this phosphorylation may modulate DNA binding. B, single image from an
animation (see Fig. S8 for full animation) showing a model of aSyn bound to DNA with 12 lysine residues labeled, using the same structural coordinates as in
(A). In this particular model, potential electrostatic interactions between lysine-21, -23, and -80 with the phosphate backbone of DNA are present. C, left,
30 nm (in diameter) phospholipid vesicle shown in the presence of no synuclein, low or high alpha-synuclein (aSyn), and high serine-129 phosphorylated
alpha-synuclein (pSyn). At low aSyn concentrations, aSyn binds the vesicle given its relatively high afﬁnity for these structures. At high aSyn concentrations,
multiple aSyn molecules are bound. To our knowledge, the effects of serine-129 phosphorylation on the interaction of aSyn with phospholipid bilayer
vesicles with a diameter of 30 nm have not yet been tested. We speculate that serine-129 phosphorylation may inhibit binding in this context. Middle,
300 bp circular DNA having a diameter of 30 nm. At low concentrations, aSyn binds DNA given its high afﬁnity for the curved negatively charged DNA
surface (due to the phosphate backbone). At high aSyn concentrations, multiple aSyn molecules are bound, analogous to their binding to phospholipid
vesicle membranes of similar geometry (left). Serine-129 phosphorylation inhibits the ability of synuclein to bind 300 bp circular DNA. Right, 300 bp linear
DNA having a length of 100 nm. At low aSyn concentrations, aSyn binds as a monomer and bends linear DNA. At high aSyn concentrations, multiple aSyn
molecules bind linear DNA and bend it into a conformation that resembles a DNA circle (middle). At high pSyn concentrations, pSyn binds as a monomer
and bends linear DNA, but is not able to bend it into a circle-like form.

and whether similarities between its binding to DNA and
curved phospholipid surfaces exist.
Several studies have tested the effects of serine-129 phosphorylation on aSyn’s membrane-binding properties. In the
context of binding synaptosomal membranes (a mixture of the
presynaptic vesicle, organelle, and plasma membranes), serine129 phosphorylation did not affect the binding of the WT aSyn
protein, but did increase the membrane binding of the diseaseassociated A30P mutation (which has reduced membrane
binding compared with WT at baseline) (68). Work in a
micelle model system produced similar results: that serine-129
phosphorylation did not affect lipid-bound aSyn, but could
disrupt long-range N- and C-terminal interactions within the
protein when it is not lipid-bound (69). This argues that longrange N- and C-terminal interactions in the protein occur and
can be modulated by phosphorylation. In contrast, other work
suggests that serine-129 phosphorylation does inhibit binding
to certain membranes, such as ER, Golgi, and mitochondrial
membranes in neurons (70) or plasma membranes in yeast
(71). In planar lipid nanodisc (72) and unilamellar vesicle (73)
systems, the alpha-synuclein C-terminus was disordered even
without serine-129 being phosphorylated. Unfortunately, to
our knowledge, the potential effects of serine-129

phosphorylation on isolated presynaptic vesicles, or model
spherical phospholipid bilayer systems with similar chemical
composition and 20 to 40 nm (in diameter) geometry, have
not been tested to date. Our data showing that aSyn binds
304 bp circular DNA, which has a similar geometry to 30 nm
synaptic vesicles, while pSyn does not, lead us to propose a
model where high concentrations of aSyn favor the formation
of circle-like DNA structures (Fig. 8C). We also speculate,
based on potential analogies between DNA circle and phospholipid vesicle binding, that serine-129 phosphorylation may
reduce aSyn binding to presynaptic vesicles, as it does for
circular DNA (Fig. 8C). It is possible in disease, where aSyn’s
ability to properly bind synaptic vesicles could be compromised (35), that a similar deﬁciency in properly binding and
bending DNA also occurs and leads to detrimental cellular
consequences due to the dysregulation of nuclear processes
that require these synuclein–DNA interactions. It will be
interesting in future work to directly test the validity of our
proposed model by using other techniques that are complementary to the primarily EMSA approaches we have used here.
For example, examining the high-resolution structure of aSyn
bound to linear and circular DNA forms, potentially using
X-ray diffraction or rapidly advancing cryo-EM approaches,
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could allow direct visualization of the synuclein–DNA complex. Also, since EMSA is a biochemical technique requiring
puriﬁed components, it cannot directly measure synuclein–
DNA interactions within the cellular milieu. It will also be
important in the future to study these interactions using other
biophysical and cell biological approaches that can assay and
measure the potential functional consequences of aSyn binding and bending nuclear DNA.
Previous work has also suggested that phosphorylation of
aSyn by Polo-like kinases (PLK) can play important roles in
regulating the amount present in the nucleus, and that the PLK
family member PLK2 speciﬁcally phosphorylates serine-129 in
the soluble nuclear fraction (74). This effect is likely complicated, however, since either overexpressing PLK2 or PLK3 (57)
or genetically deleting PLK2 (75) produces data consistent
with alpha-synuclein phosphorylation at serine-129 by these
kinases as promoting export of synuclein from the nucleus and
into the cytoplasm. In contrast, other work suggests that when
synuclein is forced into the nucleus by fusing it with a nuclear
localization sequence and then mutated at serine-129 to the
unphosphorylatable residue alanine, accumulation in the
cytoplasm is promoted (7). Further work is required to understand the details of synuclein shuttling between the nuclear
and cytoplasmic compartments, but these data suggest that the
identity of the kinase phosphorylating serine-129 or other
cophosphorylation events on other residues of the protein
could be important for the direction in which it travels (into or
out of the nucleus).
Our data suggest a new framework for understanding the
role of aSyn in the nucleus and its biophysical interactions with
the DNA located there. The ability of aSyn to bend DNA into
distinct circle-like conformations may play a role in how it
inhibits transcription from speciﬁc promoters (7, 42, 50) and/
or facilitates forms of DSB repair (9). Our work also highlights
the important role of serine-129 phosphorylation in regulating
this process, acting as a potential switch that causes aSyn to
unbind from DNA, and therefore allowing the DNA to relax
from a circle-like conformation into a more linear state.
Further exploration of these processes could help elucidate the
poorly understood functions of nuclear aSyn and how they
may be relevant to important forms of neurodegeneration and
cancer.

Experimental procedures
Reagents
EMSA reaction buffers and protein storage buffers were
formulated using either MilliQ puriﬁed H2O or ﬁltered molecular biology grade H2O (0.1 μm ﬁlter). pH was determined
using a pH meter and adjusted with 1 M HCl or 5 M NaOH
before vacuum ﬁltration (0.2 μm ﬁlter). Electrophoresis buffers
were made with MilliQ puriﬁed H2O and 10× TBE or 50× TAE
stock solutions.
DNA generation
300 bp linear and 304 bp circular double-stranded DNAs
were created using the 300 bp band from a 100 bp ladder
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(New England Biolabs, cat. # N3231) as the template DNA.
After each extraction and synthesis step described, constructs
were cleaned using the QIAquick PCR clean-up kit (Qiagen,
cat. # 28104) according to the manufacturer’s protocol. An
extra wash step and two extra spin steps were added before
elution of DNA into buffer in the Qiagen protocol to reduce
ethanol contamination. The ﬁnal products were eluted into
H2O, 1× TE or Buffer EB (Qiagen; 10 mM Tris, pH 8.5) and
stored at −20  C until use. The concentration and purity of
DNA were determined by obtaining 260/280 nm and 260/
230 nm readings with a Nanodrop spectrophotometer. 125,
200, 300, 400, and 500 bp linear DNA used for testing length
dependence and 300 bp DNA with varying GC content were
synthesized using gBlocks (IDT).
Gel extraction
100 bp DNA ladder (New England Biolabs, cat. # N3231) in
1× Orange Loading Dye (Li-Cor, cat. # 927-10100) was separated on a 1.5% TAE agarose gel in 1× TAE at 175 V (2 h at
room temperature, RT) in the presence of 1× Sybr Safe
(Invitrogen, cat. # S33102) using the QIAquick Gel Extraction
Kit (Qiagen, cat. # 28704) using the manufacturer’s recommended protocol, with the addition of two extra wash and spin
steps to minimize ethanol contamination before ﬁnal elution.
Polymerase chain reaction
Between 10 and 100 ng of 300 bp template DNA was added
to 1 μM of forward and reverse primers (IDT, forward:
50 TCGAGCAGGCAGAACGG 30 , reverse: 50 TGCCTGGT
AGGCGTCC 30 ) using 1× Phusion HF PCR Master Mix with
HF Buffer (New England Biolabs, cat. # M0531). 300 bp linear
dsDNA with additional 4 base 50 overhangs on each end were
generated from our 300 bp template DNA using PCR primers
(IDT, forward: 50 TTAATGAATTCGAGCAGGCAGAAC 30 ,
reverse: 50 AATTAGAATTCTGCCTGGTAGGCGT 30 ) that
created a 320 bp dsDNA with EcoRI restriction enzyme sites
on each end. When cut with EcoRI (1–16 h at 37  C, EcoRIHF, New England Biolabs, cat. # R3101), the 300 bp linear
dsDNA with the 4 base 50 overhanging ends was produced and
the reaction stopped with Proteinase K treatment (1 h at 37  C,
New England Biolabs, cat. # P8111). All DNA was cleaned
using the QIAquick PCR clean-up kit (Qiagen, cat. # 28104)
before use.
Circular DNA preparation
Cleaned 300 bp dsDNA with the 4 base 50 overhanging ends
was created as above and treated with T4 ligase (New England
Biolabs, cat. # M0202), either in the absence or presence of
HMGB1 (Biolegend, cat. # 557804), using the manufacturer’s
recommended protocol (24 h at 37  C). Ligase reactions were
stopped with Proteinase K treatment (1 h at 37  C, New England Biolabs, cat. # P8111) and then cleaned using the QIAquick PCR clean-up kit (Qiagen, cat. # 28104). Linear species
remaining in the sample were removed using either T5 or T7
exonuclease (New England Biolabs, cat. # M0363, M0263)
using the manufacturer’s recommended protocol.
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Electrophoretic mobility shift assay
All recombinant proteins used for EMSA experiments were
handled according to manufacturers’ recommendations. Human aSyn and pSyn proteins (Proteos, cat. # RP-003, RP-004)
and human aSyn, bSyn, gSyn, A30P, E46K, A53T, deltaNAC
aSyn (rPeptide, cat. # S-1001, S-1003, S-1007, S-1005, S-1008,
S-1002, S-1015) were stored at −80  C. Glutathione S-transferase (GenScript, cat. # Z02039) and DNA were stored at −20

C. All DNA created using the 300 bp template DNA had
260/280 nm readings between 1.8 and 2.0, and 260/230 nm
readings between 2.0 and 2.2. Protein–DNA incubation components were added in the following order: (1) buffer master
mix, (2) recombinant protein, and (3) DNA. The ﬁnal EMSA
buffer solution contains 11 mM Tris, 1 mM EDTA, 50 mM
NaCl, pH 8.0 to 8.5. Incubation occurred for 20 min on ice
followed by 30 min at RT. For major and minor groovebinding dye experiments, incubations occurred for an additional 30 min at RT with the indicated DNA-binding dye
(Hoechst 33258, Thermo Fisher, cat. # H1398; methyl green,
Sigma-Aldrich, cat. # 198080). After the addition of 2 μl 10×
Orange Loading Buffer (Li-Cor, cat. # 927-10100), samples
were loaded into 6%, 10%, or 20% polyacrylamide Novex TBE
gels (Invitrogen) and run in 1× TBE. All gels were poststained
for 30 min at RT on a rotator with 1 to 10× Sybr Gold DNA
Stain (Invitrogen, cat. # S11494) or Sybr Safe DNA Stain
(Invitrogen, cat. # S33102) in 1× TBE. Images were acquired
using a Fluorchem M (Protein Simple) imaging system and
quantiﬁed using ImageJ (NIH) Gel Analyzing tool.
aSyn point mutation and deltaNAC EMSA protocol: rPeptide EMSA reactions contain 10 ng of a linear 300 bp fragment
of DNA that was PCR ampliﬁed and cleaned up (Qiagen), 0.5%
Ficoll 400 (Sigma cat. F4375), 4 μl of protein or buffer [20 mM
Tris-HCl, 200 mM NaCl], and dH2O to a total volume of 10 μl.
A master mix of 5% ﬁcoll 400, DNA, and dH2O is added to a
PCR reaction tube containing diluted protein and/or buffer.
The reaction tube is gently ﬂicked to mix. One microliter of
LICOR 10× Orange loading dye (cat. 92710100) is added to the
reaction and 8 μl loaded per lane of a Novex 10% TBE gel (cat.
EC62755BOX). The gel is run in 0.5× TBE buffer (Corning,
cat. 46-011-CM) at 100 V for 70 min, poststained in 1× SYBR
Gold (Invitrogen cat. S11494) for 15 min, and imaged on a
FluorChem ProteinSimple imager using the green 547 nm
ﬁlter. The gel is then ﬁxed for 30 min in 40% methanol, 10%
acetic acid, followed by poststaining overnight with Biorad
Bio-Safe Coomassie G-250 Stain (cat. 1610786). After washing
in dH2O, the gel is imaged on a LICOR Odyssey in the 700
channel. Gels are analyzed using ImageJ (NIH) Gel Analyzing
tool.
Western blot and Coomassie stain
In total, 6% and 10% polyacrylamide TBE gels were transferred onto a Biodyne B Nylon Membrane (Thermo Fisher
Scientiﬁc, cat. # 77016) at 30 to 35 V for 1 h and 15 min on ice
in 0.5× TBE using the Novex X-Cell II Blotting System
(Invitrogen). After transfer, membranes were washed brieﬂy in

H2O and ﬁxed for 30 min at RT in Ca2+/Mg2+-free 1× PBS
containing 4% paraformaldehyde and 0.1% glutaraldehyde.
Postﬁxation, membranes were washed 3× (10 min each) in
Ca2+/Mg2+-free PBS containing 0.1% Triton X-100. Membranes were blocked overnight in Odyssey PBS Blocking Buffer
(Li-Cor, cat. # 927-40000) and stained for 1 h at RT with Syn1
primary antibody (1:1000; BD Biosciences, cat. # 610787) and
overnight at 4  C with IRDye 800CW Goat anti-Mouse IgG
secondary antibody (1:10,000; Li-Cor, cat. # 926-32210). Images were acquired using Li-Cor Odyssey CLx Imaging System.
After DNA imaging, some gels were washed 1× (5 min) in
MilliQ H2O and stained in 15 to 20 ml of Coomassie G250
Safestain (Bio-Rad, cat. # 1610786) overnight at 4  C on a
rotator. Gels were washed 2× (1 h, then 2 h) in MilliQ H2O.
Images were acquired using a Li-Cor Odyssey CLx Imaging
System.
Transmission electron microscopy
Five microliters of DNA suspensions was deposited onto
glow discharged (120 s 15 mAmp, negative mode) carbon
formvar 400 Mesh copper grids (Ted Pella 01822-F) for 3 min,
rinsed 10 s in water, wicked on Whatman ﬁlter paper 1, stained
for 3 min in freshly prepared 1% (w/v) uranyl acetate in water,
wicked, and air-dried. Samples were imaged at 120 kV on a FEI
Tecnai Spirit TEM system. Images were acquired using the
AMT interface on an AMT 12 Megapixel NanoSprint12S-B
cMOS camera system.
Atomic force microscopy
Five nanograms of 300 bp linear DNA suspended in the
same buffer used for the EMSA assay (see above), with the
addition of 5 mM MgCl2, was deposited on a mica surface
without the presence of aSyn. Similar experiments using
57 μM aSyn with 5 ng of 300 bp linear DNA (suspended in
3 mM HEPES at pH 8.0 with 10 mM NaCl, 2 mM MgCl2) were
performed after deposition on silicon surfaces. AFM samples
were prepared using 10 μl of the DNA solution. First, 5 μl of a
5 mM MgCl2 solution was deposited dropwise onto freshly
cleaved mica or silicon and dried under a clean ﬂux of N2 gas.
This was followed by the deposition of 5 μl of the DNA-MgCl2
solution onto the surface, which was dried with N2 gas. The
sample was then rinsed with NANOpure H2O to remove
excess salt and loosely bound DNA and dried under N2 gas.
The same procedure was used for samples containing alphasynuclein and DNA that were allowed to incubate for
10 min before casting onto the surface. Imaging was performed using Digital Instruments Veeco AFM/LFM Instrument (Veeco Metrology group). Rotated monolithic, uncoated
silicon AFM probes were used with 125 μm tip length,
300 kHz resonant frequency, and a 40 Newton/meter spring
constant model Tap300-G (Ted Pella Inc). The instrument was
operated in tapping mode while keeping drive amplitude to a
minimum, collecting scans of 2 μm × 2 μm at a slow scan
frequency of 1.5 to 2.5 Hz and 512 × 512 scans per line. AFM
images were analyzed using Digital Instruments software.
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Experimental design and statistical analysis
All quantiﬁed values are reported as the mean ± SD. The
relevant sample type, number (N), and statistical tests used to
evaluate signiﬁcance for each experiment are presented with
each data set.
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Data availability
All data are presented in the article and the supplementary
information.
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